Point72 Hong Kong’s Phathom Pharmaceuticals PHAT Stock Holding History

Point72 Hong Kong’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-39	Closed	–	–	1276
2022 Q3	$0	Buy	+39	New	+$372	﹤0.01%	2306

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Point72 Hong Kong's PHAT Position: Q4 2022 in Review

Point72 Hong Kong sold out of Phathom Pharmaceuticals (PHAT) in Q4 2022, closing a stake of 39 shares.

Point72 Hong Kong first reported a position in PHAT in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 87 funds tracked by Wall St. Rank hold PHAT as of Q4 2022.

Point72 Hong Kong reported no remaining Phathom Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Point72 Hong Kong sold 39 Phathom Pharmaceuticals shares in Q4 2022.
Point72 Hong Kong first reported a position in Phathom Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Point72 Hong Kong's Phathom Pharmaceuticals position peaked at $0 in Q3 2022.
87 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.